SCHEMBL7112980

SCHEMBL7112980

NC(C(=O)O)S(=O)(=O)c1csc2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
MAPT P10636 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
PKM P14618 1/20 0.39
APP P05067 1/20 0.38
CYP2A6 P11509 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31287752 0.73 CA2 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2703947 0.73 CYP2A6 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1034849 0.73 CA2 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6572028 0.73 SLC1A3 (0.57) CA1CA2ALDH1A1HTTSLC1A3
SCHEMBL28046230 0.72 TTR (0.45) HDAC3HSD17B10SLC1A3SLC1A2SLC1A1
SCHEMBL6766434 0.72 CYP2A6 (0.46) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6617627 0.72 CYP2A6 (0.46) HDAC3HDAC4HDAC1HDAC7HDAC2
Hydrochloric Acid SCHEMBL27734063 0.72 CYP2A6 (0.46) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4251872 0.71 ALOX5 (0.54) ALOX5HDAC3HDAC4HDAC1HDAC7
SCHEMBL14089195 0.70 CYP2A6 (0.46) ALOX5HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800623-B2 A 1,3-DITHIA-4-AZA-ACENAPHTHYLENE 3,3-DIOXIDE COMPOUNDS; TREATING PSYCHOLOGICAL DISORDERS BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-10-05 US disclosed
US-20030158183-A1 Method of treating schizophrenia BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-08-21 US disclosed
US-20030158181-A1 Method for treating cerebral ishaemia BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-08-21 US disclosed
US-6525045-B2 4,5-dihydro-1,3-dithia-4-aza-acenaphthylene-3,3-dioxide compounds for example; treating ischemia, Alzheimer's disease, schizophrenia; alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-02-25 US disclosed
US-20020013313-A1 4,5-dihydro-1,3-dithia-4-aza-acenaphthylene-3,3-dioxide compounds for example; treating ischemia, Alzheimer's disease, schizophrenia; alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158183-A1 Method of treating schizophrenia GRIN2A, GRIN1, CHAT ALOX5 2416/4885HDAC3 1382/4885HDAC4 1330/4885
US-20020013313-A1 4,5-dihydro-1,3-dithia-4-aza-acenaphthylene-3,3-dioxide compounds for example; treating ischemia, Alzheimer's disease, schizophrenia; alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) GRIA4, GRIN1, GRIN3A ALOX5 2073/4885HDAC3 1090/4885HDAC4 1052/4885
US-20030158181-A1 Method for treating cerebral ishaemia PYGB, DCX, INA ALOX5 4250/4885HDAC3 1124/4885HDAC4 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.